GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shortwave Life Sciences PLC (AQSE:PSY) » Definitions » Minority Interest

Shortwave Life Sciences (AQSE:PSY) Minority Interest : £0.00 Mil (As of . 20)


View and export this data going back to 2022. Start your Free Trial

What is Shortwave Life Sciences Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Shortwave Life Sciences's minority interest for the quarter that ended in . 20 was £0.00 Mil.

Shortwave Life Sciences Minority Interest Historical Data

The historical data trend for Shortwave Life Sciences's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shortwave Life Sciences Minority Interest Chart

Shortwave Life Sciences Annual Data
Trend
Minority Interest

Shortwave Life Sciences Semi-Annual Data
Minority Interest

Shortwave Life Sciences Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Shortwave Life Sciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shortwave Life Sciences PLC (AQSE:PSY) » Definitions » Minority Interest
Comparable Companies
Traded in Other Exchanges
N/A
Address
17 Hanover Square, London, GBR, W1S 1BN
Website
https://www.shortwavelifesciences.com
Shortwave Life Sciences PLC is a biopharmaceutical company focused in advancing pioneering therapies in mental health care, also it is involved in developing novel drug combinations and delivery methods to treat patients suffering from mental health disorders. It identifies, operates and creates value from early-stage, breakthrough initiatives, with an initial focus on eating disorders.

Shortwave Life Sciences Headlines